Truist Financial Upgrades Sutro Biopharma (NASDAQ:STRO) to Strong-Buy

Sutro Biopharma (NASDAQ:STRO) was upgraded by equities researchers at Truist Financial to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on STRO. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Wells Fargo & Company upgraded Sutro Biopharma from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $8.00 to $27.00 in a research note on Tuesday. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target for the company in a report on Tuesday, January 20th. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Wedbush restated a “neutral” rating and set a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma currently has an average rating of “Moderate Buy” and an average target price of $37.29.

Sutro Biopharma Trading Up 6.0%

NASDAQ STRO opened at $24.91 on Wednesday. The firm’s fifty day simple moving average is $18.84 and its two-hundred day simple moving average is $12.84. The firm has a market capitalization of $212.08 million, a P/E ratio of -0.95 and a beta of 1.47. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54.

Hedge Funds Weigh In On Sutro Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Velan Capital Investment Management LP lifted its position in Sutro Biopharma by 2.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after acquiring an additional 60,000 shares during the period. UBS Group AG grew its stake in Sutro Biopharma by 14.0% during the 3rd quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock valued at $1,602,000 after purchasing an additional 226,955 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares during the period. Jane Street Group LLC acquired a new position in shares of Sutro Biopharma in the second quarter valued at about $492,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Sutro Biopharma in the third quarter worth about $387,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma News Roundup

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target to $55 from $51 and maintained a “Buy” rating — a sizable upside vs. the current price, which supports bullish sentiment. Benzinga
• Positive Sentiment: Truist Financial upgraded Sutro to “Strong-Buy,” reinforcing buy-side momentum among institutional analysts. Zacks
• Positive Sentiment: Wells Fargo upgraded STRO to “Overweight,” adding another supportive brokerage view that can attract investors. Wells Fargo Upgrade
• Positive Sentiment: HC Wainwright also issued an upgrade/coverage item (Buy, $28 PT) in recent press coverage, adding to the cluster of buy-side recommendations. AmericanBankingNews – HC Wainwright Upgrade
• Neutral Sentiment: HC Wainwright published a FY2030 estimate (EPS forecast of ($4.43)), which is informational for longer-term modeling but not a catalyst on its own. MarketBeat
• Negative Sentiment: Offsetting the upgrades, HC Wainwright sharply lowered near- and multi-year EPS forecasts across Q1–Q4 2026 and FY2026–FY2029 (e.g., FY2026 cut to ($10.32) from ($4.25); FY2027–FY2029 also pushed materially lower), while retaining a Buy rating and $28 PT — these large downside revisions imply greater near-term dilution, higher cash burn or program changes and represent a negative earnings/cash-flow signal investors should model into valuations. MarketBeat – Estimates

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.